BNET Industries
Schering-Plough Corp. (SGP) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $12.6B
- Profit
- Dec 31 2007
- ($1.4B)
- Market Cap
- Sep 04 2008
- $31.1B
Latest News and Analysis
Schering Plough, Merck: Potential Cancer Concerns
Mark Barath submits: In a post on August 8th, I advocated purchasing Schering Plough SGP and I spelled out my reasoning. In that post, I explained investor concerns of Vytorin. At that time, the ENHANCE panel found that Vytorin, a combination of Merck’s MRK Zocor and Schering’s Zetia, worked no...
Heart Experts Clash on Vytorin and Cancer Risk
By Ben Hirschler MUNICH (Reuters) - Experts clashed on Tuesday over the safety of Merck & Co MRK and Schering-Plough Corp's SGP cholesterol drug Vytorin as full results from a controversial study were presented at Europe's biggest medical congress. Researchers involved in the...
China's Hepatitis B Market to Double by 2012
ChinaBio Today submits: The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%....
Is a Hurricane Lurking for Merck and Schering-Plough?
Mike Huckman submits: This won't be much of an end-of-summer holiday weekend for the folks at Merck MRK and Schering-Plough SGP. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test...
Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising
Derek Lowe submits: Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, which has sat down to estimate how well various drug companies will do with revenue from new drugs...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
China Biotech Week in Review: Earnings, Earnings, Earnings
ChinaBio Today submits: Last week was a big week for earning announcements from China life science enterprises: a total of eight companies announced their results. Earnings reports far overshadowed almost any other kind of news from the China life sciences sector. For the most part, the eight companies posted...
Why Schering-Plough Bought Out Its China JV
ChinaBio Today submits: Schering-Plough Corporation SGP bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their...
Schering-Plough Takes Sole Possession of Its China JV
ChinaBio Today submits: Schering-Plough Corporation SGP bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their...
Are Big Pharma's Dollar Days Nearly Over?
Mike Huckman submits: For quite some time now the major American pharmaceutical companies have been benefiting from the foreign exchange rate. Besides cost-cutting, the weak dollar has been propping up revenue and profits during a time when the sector is battling intense competition from much cheaper generic drugs, safety...
Buying Healthcare Stocks for an Obama Presidency (Part III)
Mark Barath submits: In a previous post, I spelled out why I am buying healthcare stocks for an Obama presidency. In that post, I promised to provide three stocks that would benefit from this fact. The first stock was Aetna AET and now I will discus the second stock in...
Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering's shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was "surprised...
PowerShares FTSE RAFI Healthcare: Big Bets on Dow Dogs
Don Dion submits: While the PowerShares FTSE RAFI Health Care fund PRFH has experienced a recent leap in momentum, this move may not come as a surprise to many health care investors. PRFH has jumped 20 spots, from 61 to 41, on our PowerShares Momentum Tracker Sector Momentum...
Schering Plough Corp. Q2 2008 Earnings Call Transcript
Schering Plough Corp. SGP Q2 FY08 Earnings Call
Schering-Plough Now in the Feds' Crosshairs
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
KENILWORTH, N.J., June 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation is scheduled to announce its sales and earnings results for the 2008 second quarter on Monday, July 21, 2008.
Schering-Plough Announces Fruit of the Earth to Change Sun Care Packaging After Court Hearing
DALLAS, June 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that the Federal District Court for the Northern District of Texas Dallas Division has confirmed that Fruit of the Earth must promptly change the packaging of its generic, no-name sport and baby sunscreens. Schering-Plough maintains that the Fruit of the...
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin.
Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Johnson & Johnson, Schering Plough, Colgate-Palmolive and Procter & Gamble
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Vertex Pharmaceuticals (Nasdaq: VRTX), Johnson & Johnson (NYSE: JNJ), Schering Plough...
ChemDiv to Provide Schering Plough Corporation With Discovery Libraries in Multiyear Agreement
SAN DIEGO, June 5 /PRNewswire/ -- ChemDiv announced today the continuation of multi-year collaboration with Schering Plough Corporation. In the framework of this collaboration ChemDiv will provide Schering Plough with a set of chemical libraries that will be produced through parallel synthesis based on the customer selected templates. In...
- Next »
- page 1 of 30
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Stock (64 results)
- Hackensack (45 results)
- Merck & Co. Inc. (29 results)
- agreement (28 results)
- FDA (25 results)
- New York Stock Exchange (15 results)
- pharmaceutical company (14 results)
- Tyco International Ltd. (13 results)
- manufacturing (12 results)
- class action (12 results)
- company (12 results)
- marketing (11 results)
- collaboration (11 results)
- Pfizer Inc. (11 results)
- Sales (11 results)
- The Walt Disney Co. (10 results)
- Exxon Mobil Corp. (9 results)
- PeopleSoft Inc. (9 results)
- Network Appliance Inc. (8 results)
- blog (8 results)
- Healthcare (8 results)
- patent (8 results)
- S&P 500 (8 results)
- Novartis AG (8 results)
- Shareholder (8 results)
- Cendant Corp. (8 results)
- Finance (7 results)
- Texas Instruments Inc. (7 results)
- Patient (7 results)
- therapy (7 results)
- health care (7 results)
- Eli Lilly & Co. (6 results)
- Bristol-Myers Squibb Co. (6 results)
- Schering (6 results)
- earnings (6 results)
- BEA Systems Inc. (5 results)
- GlaxoSmithKline Plc. (5 results)
- KLA-Tencor Corp. (5 results)
- Call Transcript (5 results)
- alliance (5 results)
- advertisement (5 results)
- acquisition (5 results)
- IBM Corp. (5 results)
- Seeking Alpha (5 results)
- J.P. Morgan Chase & Co. (5 results)
- Financial Accounting (5 results)
- Novellus Systems Inc. (5 results)
- SEC (5 results)
- supply chain (5 results)
- life science (5 results)
- Incorporated: 1970
- CEO: Mr. Fred Hassan
Schering-Plough is a science-centered health care company operating through three business segments. Co.'s Human Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. Co.'s Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products. Co.'s Animal Health segment discovers, develops, manufactures and markets animal health products including vaccines. As of Dec 31 2007, Co. had subsidiaries in more than 55 countries outside the U.S. In addition, as of Dec 31 2007, Co. had business operations in more than 140 countries.
Key Competitors
Schering-Plough Corp. Company Info
Board of Directors
Mr. Fred Hassan
Chairman
Dr. Craig B. Thompson
Ms. Kathryn C. Turner
Mr. Robert F. W. van Oordt
Mr. Arthur F. Weinbach
Mr. Hans W. Becherer
Mr. Thomas J. Colligan
Mr. C. Robert Kidder
Mr. Eugene R. McGrath
General Carl E. Mundy Jr.
Mr. Antonio M. Perez
Ms. Patricia F. Russo
Mr. Jack L. Stahl
Contact Information
2000 Galloping Hill Road
Kenilworth, NJ
http://www.schering-plough.com
908 298-4000